Sustained-release bupropion overdose: A new entity for Australian emergency departments

Authors: Paoloni, Richard; Szekely, Ilona1

Source: Emergency Medicine, Volume 14, Number 1, March 2002 , pp. 109-112(4)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Bupropion hydrochloride (Zyban, Glaxo Wellcome Australia, Melbourne, Vic., Australia) was released in Australia in November 2000 as adjunctive therapy to assist with smoking cessation, having previously been used as an antidepressant in the US since 1989. The toxicity profile of bupropion hydrochloride in overdose differs considerably from other antidepressants, with prominent neurological manifestations and little cardiovascular toxicity. A case of bupropion overdose demonstrating the typical toxic syndrome is presented, together with a review of the literature and a discussion of the magnitude of the demand for bupropion and of the potential differences in presentation of overdoses in Australia.

Keywords: bupropion; overdose

Document Type: Research article

DOI: 10.1046/j.1035-6851.2001.00295.x

Affiliations: 1: Department of Emergency Medicine, Concord Repatriation General Hospital, Concord, New South Wales, Australia

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A